RAS AL KHAIMAH: Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has announced its second quarter 2019 financial results.
The company reported Q2 2019 net sales of AED 100 million and a net loss of AED 96m.
Jerome Carle, CEO of Julphar, said: "Firstly, I wish to express my gratitude to our shareholders, our employees, our customers and our partners for their continued support.
"Our second quarter performance was disappointing primarily due to continued challenges in Saudi Arabia coupled with unfavorable conditions in some of our key markets. However, we have started a transformation that will make us stronger in the long run.
"We remain cautious in our outlook but we are confident we are taking the right actions to ensure a full recovery and achieve our long term objectives."
Julphar's revenue was negatively impacted by the Saudi Food & Drug Authority's temporary ban on the export of the company's products to the Kingdom in September 2018. Consequently, the company's management has focused on cost reductions and has taken several actions to strengthen the organization and maximize cash flows.
Earlier, the Company announced the appointment of new executive employees to help guide the company towards profitability and long-term success.
About Julphar
Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa and for almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 5,000 people and distributes pharmaceutical products to more than 50 countries on five continents.
Julphar's business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism.
Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicine a day. In 2012, Julphar became one of the largest producers of Insulin with its UAE-based Biotechnology production unit based.
For more information, visit http://www.julphar.net.
Contact:
Chris Goward
chris.goward@julphar.net
+971-(0)58-263-3997
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
